← Alpha Teknova, Inc. (TKNO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Alpha Teknova, Inc. (TKNO)
In Vitro & In Vivo Diagnostic Substances · market cap $493M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Alpha Teknova, Inc. (TKNO) is a diagnostics-sector company with a market cap of ~$276M and ~53.6M shares outstanding at ~$5.15. The company generates ~$41M in annual revenue but has posted consistent net losses every year since at least 2021, and carries only $4.3M in cash against $8.9M in net debt — implying a runway of roughly 3.8 months. Its pipeline centers on AZD3759, a Phase 2 asset in Non-Small Cell Lung Cancer.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AZD3759 | Phase 2 | Non Small Cell Lung Cancer |
Price & technical context
3-month
+53.0%
6-month
+202.4%
12-month
+43.1%
52-wk range
$1.99–$9.33
vs 50-day MA
+25.7%
vs 200-day MA
+96.2%
Realized vol
75.9%
Max drawdown
-79.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TKNO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.